

Global Gene Fusion Testing Market

<https://marketpublishers.com/r/G8D46C872C16EN.html>

Date: December 2025

Pages: 79

Price: US\$ 2,950.00 (Single User License)

ID: G8D46C872C16EN

Abstracts

Summary:

This report provides detailed information on the global gene fusion testing market. It highlights current and future market trends, as well as a comprehensive competitive landscape. The report analyzes market trends with data from 2024, estimates from 2025, and projections of compound annual growth rates (CAGRs) through 2030.

The report provides an overview of the gene fusion testing market and analyzes market trends. It includes global revenue (\$ million) using 2024 as the base year, estimated data for 2025 and projected data for 2026 through 2030.

The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.

The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.

The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.

Report Scope

The report provides an overview of the gene fusion testing market and analyzes market trends. It includes global revenue (\$ million) using 2024 as the base year, estimated data for 2025 and projected data for 2026 through 2030.

The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.

The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.

The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.

Report Includes

Overview and an analysis of the global market for gene fusion testing technologies

Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030

Understanding of the technology background for fusion genes, their applications in cancer research and long-read transcriptome sequencing data

Estimates of the current market size and revenue prospects, along with a corresponding market share analysis based on the technology type, disease indication, end user and region

Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors

Insights derived from Porter's Five Forces model, as well as global supply chain analyses

Patent review, featuring key granted and published patents

Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies

Profiles of the leading companies in the market

Contents

CHAPTER 1 EXECUTIVE SUMMARY

Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Technological Advances
Conclusion

CHAPTER 2 MARKET OVERVIEW

Overview
Porter's Five Forces Analysis
Potential for New Entrants (Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (High)
Threat of Substitutes (Low)
Competition in the Industry (High)
Macroeconomic Factors Analysis
Healthcare Spending
Aging Population
U.S. Tariff Scenario

CHAPTER 3 MARKET DYNAMICS

Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Rising Adoption of Personalized Medicine
Market Restraints
High Cost of Advanced Testing Method
Complex Reimbursement Coverage of Gene Fusion Testing
Market Opportunities
Emerging Markets
Increasing Awareness and Early Cancer Detection Programs

Market Challenges
Shortage of Skilled Professionals

CHAPTER 4 EMERGING TECHNOLOGIES AND DEVELOPMENTS

Emerging Technologies
Single-Molecule Long-Read Sequencing
CRISPR-Based Fusion Detection
Digital PCR (dPCR) and Multiplex qPCR Assays
Artificial Intelligence (AI)

CHAPTER 5 MARKET SEGMENTATION ANALYSIS

Segmentation Breakdown
Market Analysis by Technology
Key Takeaways
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescence in Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Market Analysis by Indication
Key Takeaways
Solid Tumor
Hematological Cancer
Market Analysis by End User
Key Takeaways
Pharmaceutical and Biotechnology Companies
Hospitals and Diagnostic Laboratories
Academic and Research Centers
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America

CHAPTER 6 COMPETITIVE INTELLIGENCE

Key Takeaways
Competitive Landscape
Leading Companies of Gene Fusion Testing Market
Key Developments and Strategies

CHAPTER 7 APPENDIX

Methodology
Sources
Abbreviations
Company Profiles
AMOY DIAGNOSTICS CO. LTD.
BIOCARE MEDICAL LLC.
BIOCARTIS
F. HOFFMANN-LA ROCHE LTD.
GUARDANT HEALTH INC.
ILLUMINA INC.
INTEGRATED DNA TECHNOLOGIES INC.
MYRIAD GENETICS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
Few Emerging Startups/Market Disruptors

List Of Tables

LIST OF TABLES

Summary Table : Global Market for Gene Fusion Testing, by Region, Through 2030

Table 1 : Common Fusion Genes Identified Across Various Cancer Types

Table 2 : Gene Fusion Testing: Comparison of Various Technologies

Table 3 : Porter's Five Forces Analysis: Overview

Table 4 : Cancer Incidence, by Type, 2022

Table 5 : FDA-Approved Targeted Therapies for Gene Fusion-Driven Cancers

Table 6 : Gene Fusion Testing Cost, by Technology, 2024

Table 7 : Global Market for Gene Fusion Testing, by Technology, Through 2030

Table 8 : NGS in Gene Fusion: DNA versus RNA

Table 9 : PCR in Gene Fusion: Overview

Table 10 : FISH in Gene Fusion: Overview

Table 11 : IHC in Gene Fusion: Overview

Table 12 : Global Market for Gene Fusion Testing, by Indication, Through 2030

Table 13 : Gene Fusion-Targeted Therapies and FDA Companion Diagnostics

Table 14 : Hematological Gene Fusion Testing Products

Table 15 : Global Market for Gene Fusion Testing, by End User, Through 2030

Table 16 : Global Market for Gene Fusion Testing, by Region, Through 2030

Table 17 : North American Market for Gene Fusion Testing, by Technology, Through 2030

Table 18 : North American Market for Gene Fusion Testing, by Indication, Through 2030

Table 19 : North American Market for Gene Fusion Testing, by End User, Through 2030

Table 20 : European Market for Gene Fusion Testing, by Technology, Through 2030

Table 21 : European Market for Gene Fusion Testing, by Indication, Through 2030

Table 22 : European Market for Gene Fusion Testing, by End User, Through 2030

Table 23 : Asia-Pacific Market for Gene Fusion Testing, by Technology, Through 2030

Table 24 : Asia-Pacific Market for Gene Fusion Testing, by Indication, Through 2030

Table 25 : Asia-Pacific Market for Gene Fusion Testing, by End User, Through 2030

Table 26 : MEA Market for Gene Fusion Testing, by Technology, Through 2030

Table 27 : MEA Market for Gene Fusion Testing, by Indication, Through 2030

Table 28 : MEA Market for Gene Fusion Testing, by End User, Through 2030

Table 29 : South American Market for Gene Fusion Testing, by Technology, Through 2030

Table 30 : South American Market for Gene Fusion Testing, by Indication, Through 2030

Table 31 : South American Market for Gene Fusion Testing, by End User, Through 2030

2030

- Table 32 : Leading Provider of Gene Fusion Testing Market, 2024
- Table 33 : Gene Fusion Testing: Recent Strategic Developments, 2023–2025
- Table 34 : Report Information Sources
- Table 35 : Abbreviations Used in the Gene Fusion Testing Market Report
- Table 36 : Amoy Diagnostics Co. Ltd.: Company Snapshot
- Table 37 : Amoy Diagnostics Co. Ltd.: Product Portfolio
- Table 38 : Amoy Diagnostics Co. Ltd.: News/Key Developments, 2023–2025
- Table 39 : Biocare Medical LLC.: Company Snapshot
- Table 40 : Biocare Medical LLC.: Product Portfolio
- Table 41 : Biocartis: Company Snapshot
- Table 42 : Biocartis: Product Portfolio
- Table 43 : F. Hoffmann-La Roche Ltd.: Company Snapshot
- Table 44 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
- Table 45 : F. Hoffmann-La Roche Ltd.: Product Portfolio
- Table 46 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
- Table 47 : Guardant Health Inc.: Company Snapshot
- Table 48 : Guardant Health Inc.: Financial Performance, FY 2023 and 2024
- Table 49 : Guardant Health Inc.: Product Portfolio
- Table 50 : Guardant Health Inc.: News/Key Developments, 2025
- Table 51 : Illumina Inc.: Company Snapshot
- Table 52 : Illumina Inc.: Financial Performance, FY 2023 and 2024
- Table 53 : Illumina Inc.: Product Portfolio
- Table 54 : Illumina Inc.: News/Key Developments, 2024
- Table 55 : Integrated DNA Technologies Inc.: Company Snapshot
- Table 56 : Integrated DNA Technologies Inc.: Product Portfolio
- Table 57 : Integrated DNA Technologies Inc.: News/Key Developments, 2024
- Table 58 : Myriad Genetics Inc.: Company Snapshot
- Table 59 : Myriad Genetics Inc.: Financial Performance, FY 2023 and 2024
- Table 60 : Myriad Genetics Inc.: Product Portfolio
- Table 61 : QIAGEN: Company Snapshot
- Table 62 : QIAGEN: Financial Performance, FY 2023 and 2024
- Table 63 : QIAGEN: Product Portfolio
- Table 64 : Thermo Fisher Scientific Inc.: Company Snapshot
- Table 65 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
- Table 66 : Thermo Fisher Scientific Inc.: Product Portfolio
- Table 67 : List of a Few Emerging Startups/Market Disruptors

List Of Figures

LIST OF FIGURES

Summary Figure : Global Market Shares for Gene Fusion Testing, by Region, 2024

Figure 1 : Gene Fusion in Cancer

Figure 2 : Porter's Five Forces Analysis of the Gene Fusion Testing Market

Figure 3 : U.S. Major Expenditure, Projection and Trends, by Category, 2022–2033

Figure 4 : Gene Fusion Testing Market Dynamics

Figure 5 : Estimated Cancer Incidence Globally, Both Sexes, 2022–2050

Figure 6 : Emerging Trends/Technologies in the Gene Fusion Testing Market

Figure 7 : Global Market Shares for Gene Fusion Testing, by Technology, 2024

Figure 8 : Global Market Shares for Gene Fusion Testing, by Indication, 2024

Figure 9 : Global Market Shares for Gene Fusion Testing, by End User, 2024

Figure 10 : Global Market Shares for Gene Fusion Testing, by Region, 2024

Figure 11 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024

Figure 12 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024

Figure 13 : Guardant Health Inc.: Revenue Share, by Business Unit, FY 2024

Figure 14 : Guardant Health Inc.: Revenue Share, by Country/Region, FY 2024

Figure 15 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024

Figure 16 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024

Figure 17 : Myriad Genetics Inc.: Revenue Share, by Business Unit, FY 2024

Figure 18 : Myriad Genetics Inc.: Revenue Share, by Country/Region, FY 2024

Figure 19 : QIAGEN: Revenue Share, by Business Unit, FY 2024

Figure 20 : QIAGEN: Revenue Share, by Country/Region, FY 2024

Figure 21 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024

Figure 22 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024

I would like to order

Product name: Global Gene Fusion Testing Market

Product link: <https://marketpublishers.com/r/G8D46C872C16EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8D46C872C16EN.html>